Contracts › 75F40122C00148

75F40122C00148: To Characterize the Clinical Presentation of C-Vam/To Contrast C-Vam With Cardiac Complications of Infection With Sars-Cov-2 That the Immunization Seeks to Prevent/To Inform Best Practices for Surveillance and Monitoring for C-Vam, Including in Asymp

Awarded to New York Medical College by Food and Drug Administration (FDA).

$2.6Mobligated

$2.6Mpotential value

27 September 2027current end date

See modifications, all subcontractors and funding in FedSift →

Contract	75F40122C00148
Awardee	New York Medical College
Awarding agency	Food and Drug Administration (FDA)
Awarding office	FDA OFFICE OF ACQ GRANT SVCS
NAICS	541714 Research and Development in Biotechnology (Except Nanobiotechnology)
PSC	AN11 Health R&D Services; Health Care Services; Basic Research
Place of performance	MD
Offers received	165
Period of performance	26 September 2022 to 27 September 2027
Potential end	27 September 2027
Estimated recompete solicitation	~Q1 2027 (estimate, ~6 months before expiry)

Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.